CureVac Completes Stock Delisting Following BioNTech Acquisition

The publicly traded chapter for CureVac has officially closed. The mRNA specialist’s shares have ceased trading on public exchanges after BioNTech successfully finalized its acquisition of the company. Investors seeking exposure to CureVac’s assets and technology must now do so through BioNTech’s stock.

The technical completion of this corporate merger marks the end of CureVac’s independent market presence. BioNTech wrapped up the acquisition through a post-offer reorganization on January 6, 2026. Subsequently, the formal delisting from the Nasdaq Global Market took effect on January 16.

This process originated from a merger agreement initially announced in June 2025. During the public exchange offer, which ran from October to December 2025, a total Read more...